Vertex Pharmaceuticals
Registered Principal Details
Business Or Interest:
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.
Lobbying Interests:
Engage on access issues relating to non-opioid Pain Alternatives; access to healthcare; Awareness activities specific to Cystic Fibrosis, Sickle Cell Disease, T1D, Kidney Disease, and Pain.
CEO Name:
Reshma Kewalramani
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.
Lobbying Interests:
Engage on access issues relating to non-opioid Pain Alternatives; access to healthcare; Awareness activities specific to Cystic Fibrosis, Sickle Cell Disease, T1D, Kidney Disease, and Pain.
CEO Name:
Reshma Kewalramani
Contact
EB
Elizabeth Brunsvold
50 Northern Avenue
Boston, MA 20001
(312) 835-9997
Libby_Brunsvold@vrtx.com
http://www.vrtx.com
50 Northern Avenue
Boston, MA 20001
(312) 835-9997
Libby_Brunsvold@vrtx.com
http://www.vrtx.com
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|---|---|---|
| Elizabeth Brunsvold | Exclusive Duties No | Authorized On 1/13/2025 | Withdrawn On N/A |
| Tony Langenohl | Exclusive Duties Yes | Authorized On 1/13/2025 | Withdrawn On N/A |
| William J McCoshen | Exclusive Duties Yes | Authorized On 1/13/2025 | Withdrawn On N/A |
Lobbying Interests
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to sickle disease awareness month.
Development, drafting or introduction of a proposal related to sickle disease awareness month.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Action Intended To Affect
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
No certified reports found.
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
No legislative bills/resolutions found.
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
No topics found.
Minor Efforts
No minor efforts found.
Other Matters
No other matters found.